Arcutis Biotherapeutics Inc is a medical dermatology company... Show more
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ARQT declined for three days, in of 312 cases, the price declined further within the following month. The odds of a continued downward trend are .
The 10-day RSI Indicator for ARQT moved out of overbought territory on December 08, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on December 09, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ARQT as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ARQT turned negative on December 09, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
ARQT broke above its upper Bollinger Band on November 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in of 299 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 205 cases where ARQT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.472) is normal, around the industry mean (28.362). P/E Ratio (0.000) is within average values for comparable stocks, (51.986). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.836). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (11.534) is also within normal values, averaging (336.196).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a company, which engages in the development and commercialization of treatments for dermatological diseases.
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GGFSX | 21.30 | 0.45 | +2.16% |
| Gabelli Global Financial Services A | |||
| FFEFX | 16.56 | 0.12 | +0.73% |
| Nuveen Dividend Value R6 | |||
| MVSSX | 34.36 | 0.20 | +0.59% |
| Victory Integrity Small-Cap Value R6 | |||
| FFGGX | 42.21 | 0.12 | +0.29% |
| American Funds Global Balanced 529-F-2 | |||
| PJRCX | 9.60 | 0.01 | +0.10% |
| PGIM Quant Solutions International Eq C | |||
A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with IDYA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then IDYA could also see price increases.
| Ticker / NAME | Correlation To ARQT | 1D Price Change % | ||
|---|---|---|---|---|
| ARQT | 100% | -1.01% | ||
| IDYA - ARQT | 46% Loosely correlated | -0.24% | ||
| NUVL - ARQT | 44% Loosely correlated | +0.16% | ||
| BEAM - ARQT | 43% Loosely correlated | +0.40% | ||
| XNCR - ARQT | 43% Loosely correlated | -0.58% | ||
| XENE - ARQT | 42% Loosely correlated | +0.51% | ||
More | ||||